Oral mucosal injury caused by cancer therapies: Current management and new frontiers in research

Journal of Oral Pathology and Medicine

Volumn 43, Issue 2, 2014, Pages 81-90

  Jensen, Siri B ^a   Peterson, Douglas E ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Cancer therapy; Oral mucositis; Pathobiology; Prevention; Research; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; HUMAN; MOLECULARLY TARGETED THERAPY; MOUTH INJURY; NONHUMAN; ORAL MUCOSAL INJURY; ORAL MUCOSITIS; PATHOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; DRUG EFFECTS; MOUTH MUCOSA; NEOPLASMS; RADIATION RESPONSE; STOMATITIS;

ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; MOUTH MUCOSA; NEOPLASMS; STOMATITIS;

EID: 84892854570     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12135     Document Type: Review

References (63)

1. Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004; 100: 1995-2025.
2. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003; 98: 1531-9.
3. Bowen JM, Elad S, Hutchins RD, Lalla RV. Methodology for the MASCC/ISOO Mucositis Clinical Practice Guidelines Update. Support Care Cancer 2013; 21: 303-8.
4. Elad S, Bowen J, Zadik Y, Lalla RV. Development of the MASCC/ISOO Clinical Practice Guidelines for Mucositis: considerations underlying the process. Support Care Cancer 2013; 21: 309-12.
5. Hadorn DC, Baker D, Hodges JS, Hicks N. Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 1996; 49: 749-54.
6. Somerfield MR, Einhaus K, Hagerty KL, Brouwers MC, Seidenfeld J, Lyman GH. American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges. J Clin Oncol 2008; 26: 4022-6.
7. Al-Dasooqi N, Sonis ST, Bowen JM, et al. Emerging evidence on the pathobiology of mucositis. Support Care Cancer 2013; 21: 2075-83.
8. Mougeot JL, Bahrani-Mougeot FK, Lockhart PB, Brennan MT. Microarray analyses of oral punch biopsies from acute myeloid leukemia (AML) patients treated with chemotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; 112: 446-52.
9. Bowen JM, Gibson RJ, Keefe DM. Animal models of mucositis: implications for therapy. J Support Oncol 2011; 9: 161-8.
10. Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM. Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol 2009; 63: 239-51.
11. Yasuda M, Kato S, Yamanaka N, et al. 5-HT3 receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells. Br J Pharmacol 2013; 168: 1388-400.
12. Logan RM, Gibson RJ, Sonis ST, Keefe DM. Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol 2007; 43: 395-401.
13. Chen P, Lingen M, Sonis ST, Walsh-Reitz MM, Toback FG. Role of AMP-18 in oral mucositis. Oral Oncol 2011; 47: 831-9.
14. Sonis ST. Oral mucositis. Anticancer Drugs 2011; 22: 607-12.
15. Sonis ST. New thoughts on the initiation of mucositis. Oral Dis 2010; 16: 597-600.
16. Sonis ST. Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol 2009; 45: 1015-20.
17. Peterson DE, Keefe DM, Sonis ST. New frontiers in mucositis. Govindan R, ed. ASCO Educational Book. Alexandria, VA, USA: American Society of Clinical Oncology, 2012; 545-51.
18. Sonis ST, Tracey C, Shklar G, Jenson J, Florine D. An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Pathol 1990; 69: 437-43.
19. Sonis ST, Scherer J, Phelan S, et al. The gene expression sequence of radiated mucosa in an animal mucositis model. Cell Prolif 2002; 35(Suppl 1): 93-102.
20. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004; 4: 277-84.
21. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 1998; 34: 39-43.
22. Paris F, Fuks Z, Kang A, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001; 293: 293-7.
23. Al-Dasooqi N, Bowen JM, Gibson RJ, Logan RM, Stringer AM, Keefe DM. Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the dark agouti rat. Int J Exp Pathol 2011; 92: 357-65.
24. Sonis S, Antin J, Tedaldi M, Alterovitz G. SNP-based Bayesian networks can predict oral mucositis risk in autologous stem cell transplant recipients. Oral Dis 2013; doi:10.1111/odi.12146.
25. Stringer AM. Interaction between host cells and microbes in chemotherapy-induced mucositis. Nutrients 2013; 5: 1488-99.
26. Ye Y, Carlsson G, Agholme MB, et al. Oral bacterial community dynamics in pediatric patients with malignancies in relation to chemotherapy-related oral mucositis: a prospective study. Clin Microbiol Infect 2013; doi:10.1111/1469-0691.12287.
27. Schelenz S, Abdallah S, Gray G, et al. Epidemiology of oral yeast colonization and infection in patients with hematological malignancies, head neck and solid tumors. J Oral Pathol Med 2011; 40: 83-9.
28. Djuric M, Jankovic L, Jovanovic T, et al. Prevalence of oral herpes simplex virus reactivation in cancer patients: a comparison of different techniques of viral detection. J Oral Pathol Med 2009; 38: 167-73.
29. Baharvand M, ShoalehSaadi N, Barakian R, Moghaddam EJ. Taste alteration and impact on quality of life after head and neck radiotherapy. J Oral Pathol Med 2013; 42: 106-12.
30. Yamazaki M, Fujii S, Ochiai A. Reduction of type II taste cells correlates with taste dysfunction after X-ray irradiation in mice. J Oral Pathol Med 2010; 39: 212-8.
31. Olczak-Kowalczyk D, Daszkiewicz M, Krasuska S, et al. Bacteria and Candida yeasts in inflammations of the oral mucosa in children with secondary immunodeficiency. J Oral Pathol Med 2012; 41: 568-76.
32. Elad S, Epstein JB, Raber-Durlacher J, Donnelly P, Strahilevitz J. The antimicrobial effect of Iseganan HCl oral solution in patients receiving stomatotoxic chemotherapy: analysis from a multicenter, double-blind, placebo-controlled, randomized, phase III clinical trial. J Oral Pathol Med 2012; 41: 229-34.
33. Forster C, Aboodi G, Lipton J, Glogauer M. A non-invasive oral rinse assay predicts bone marrow engraftment and 6 months prognosis following allogeneic hematopoietic stem cell transplantation. J Oral Pathol Med 2012; 41: 165-70.
34. Lam DK, Dang D, Zhang J, Dolan JC, Schmidt BL. Novel animal models of acute and chronic cancer paa pivotal role for PAR2. J Neurosci 2012; 32: 14178-83.
35. Viet CT, Schmidt BL. Biologic mechanisms of oral cancer pain and implications for clinical therapy. J Dent Res 2012; 91: 447-53.
36. Al-Dasooqi N, Bowen JM, Gibson RJ, Logan RM, Stringer AM, Keefe DM. Selection of housekeeping genes for gene expression studies in a rat model of irinotecan-induced mucositis. Chemotherapy 2011; 57: 43-53.
37. Mougeot JL, Mougeot FK, Peterson DE, Padilla RJ, Brennan MT, Lockhart PB. Use of archived biopsy specimens to study gene expression in oral mucosa from chemotherapy-treated cancer patients. Oral Surg Oral Med Oral Pathol Oral Radiol 2013; 115: 630-7.
38. Hahn T, Zhelnova E, Sucheston L, et al. A deletion polymorphism in glutathione-S-transferase mu (GSTM1) and/or theta (GSTT1) is associated with an increased risk of toxicity after autologous blood and marrow transplantation. Biol Blood Marrow Transplant 2010; 16: 801-8.
39. Sonis S, Haddad R, Posner M, et al. Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol 2007; 43: 289-300.
40. Michelson S, Sehgal A, Friedrich C. In silico prediction of clinical efficacy. Curr Opin Biotechnol 2006; 17: 666-70.
41. Molina F, Dehmer M, Perco P, et al. Systems biology: opening new avenues in clinical research. Nephrol Dial Transplant 2010; 25: 1015-8.
42. Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin 2013; 63: 249-79.
43. Lalla RV. The MASCC/ISOO Mucositis Guidelines Update: introduction to the first set of articles. Support Care Cancer 2013; 21: 301-2.
44. Gibson RJ, Keefe DM, Lalla RV, et al. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer 2013; 21: 313-26.
45. McGuire DB, Fulton JS, Park J, et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer 2013; 21: 3165-77.
46. Nicolatou-Galitis O, Sarri T, Bowen J, et al. Systematic review of amifostine for the management of oral mucositis in cancer patients. Support Care Cancer 2013; 21: 357-64.
47. Peterson DE, Ohrn K, Bowen J, et al. Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Support Care Cancer 2013; 21: 327-32.
48. Migliorati C, Hewson I, Lalla RV, et al. Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Support Care Cancer 2013; 21: 333-41.
49. Raber-Durlacher JE, von Bültzingslöwen I, Logan RM, et al. Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Support Care Cancer 2013; 21: 343-55.
50. Nicolatou-Galitis O, Sarri T, Bowen J, et al. Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients. Support Care Cancer 2013; 21: 3179-89.
51. Yarom N, Ariyawardana A, Hovan A, et al. Systematic review of natural agents for the management of oral mucositis in cancer patients. Support Care Cancer 2013; 21: 3209-21.
52. Saunders DP, Epstein JB, Elad S, et al. Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. Support Care Cancer 2013; 21: 3191-207.
53. Jensen SB, Jarvis V, Zadik Y, et al. Systematic review of miscellaneous agents for the management of oral mucositis in cancer patients. Support Care Cancer 2013; 21: 3223-32.
54. Mucositis Study Group Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Evidence-based Clinical Practice Guidelines for Mucositis Secondary to Cancer Therapy, 2013. Available at: http://www.mascc.org/mucositis-guidelines (accessed on 11 November 2013).
55. Sonis S, Treister N, Chawla S, Demetri G, Haluska F. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 2010; 116: 210-5.
56. Ferte C, Paci A, Zizi M, et al. Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. Eur J Cancer 2011; 47: 2249-55.
57. Boers-Doets CB, Epstein JB, Raber-Durlacher JE, et al. Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist 2012; 17: 135-44.
58. Martins F, de Oliveira MA, Wang Q, et al. A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol 2013; 49: 293-8.
59. Elting LS, Chang YC, Parelkar P, et al. Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. Support Care Cancer 2013; 21: 3243-54.
60. Chuang P, Langone AJ. Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus. Am J Transplant 2007; 7: 714-7.
61. de Oliveira MA, Martins EM, Wang Q, et al. Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol 2011; 47: 998-1003.
62. Pilotte AP, Hohos MB, Polson KM, Huftalen TM, Treister N. Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors. Clin J Oncol Nurs 2011; 15: E83-E9.
63. Gordon Research Conference Mucosal Health & Disease. 2013. Available at: http://www.grc.org/programs.aspx?year=2013&program=mucosal (accessed on 11 November 2013).